• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过多色流式细胞术检测临床相关免疫检查点标志物。

Detection of clinically relevant immune checkpoint markers by multicolor flow cytometry.

作者信息

Cunningham Rachel A, Holland Martha, McWilliams Emily, Hodi Frank Stephen, Severgnini Mariano

机构信息

Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, 450 Brookline, Ave Mayer Building 305, Boston, MA 02215, USA.

出版信息

J Biol Methods. 2019 Jun 3;6(2):e114. doi: 10.14440/jbm.2019.283. eCollection 2019.

DOI:10.14440/jbm.2019.283
PMID:31453261
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6706095/
Abstract

As checkpoint inhibitor immunotherapies gain traction among cancer researchers and clinicians, the need grows for assays that can definitively phenotype patient immune cells. Herein, we present an 8-color flow cytometry panel for lineage and immune checkpoint markers and validate it using healthy human donor peripheral blood mononuclear cells (PBMCs). Flow cytometry data was generated on a BD LSR Fortessa and supported by Luminex multiplex soluble immunoassay. Our data showed significant variation between donors at both baseline and different stages of activation, as well as a trend in increasing expression of checkpoint markers on stimulated CD4 and CD8 T-cells with time. Soluble immune checkpoint quantification assays revealed that LAG-3, TIM-3, CTLA-4, and PD-1 soluble isoforms are upregulated after stimulation. This 8-color flow cytometry panel, supported here by soluble immunoassay, can be used to identify and evaluate immune checkpoints on T-lymphocytes in cryopreserved human PBMC samples. This panel is ideal for characterizing checkpoint expression in clinical samples for which cryopreservation is necessary.

摘要

随着检查点抑制剂免疫疗法在癌症研究人员和临床医生中越来越受到关注,对能够明确鉴定患者免疫细胞表型的检测方法的需求也日益增加。在此,我们展示了一种用于谱系和免疫检查点标志物的8色流式细胞术检测方案,并使用健康人类供体的外周血单核细胞(PBMC)对其进行了验证。流式细胞术数据是在BD LSR Fortessa上生成的,并得到了Luminex多重可溶性免疫测定的支持。我们的数据显示,在基线和不同激活阶段,供体之间存在显著差异,并且随着时间的推移,刺激后的CD4和CD8 T细胞上检查点标志物的表达有增加的趋势。可溶性免疫检查点定量检测显示,刺激后LAG-3、TIM-3、CTLA-4和PD-1可溶性异构体上调。这种由可溶性免疫测定支持的8色流式细胞术检测方案可用于鉴定和评估冷冻保存的人类PBMC样本中T淋巴细胞上的免疫检查点。该检测方案非常适合用于对需要冷冻保存的临床样本中的检查点表达进行表征。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8a5/6706095/ce5ae7b060ff/jbm-6-2-e114-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8a5/6706095/a915cec8790e/jbm-6-2-e114-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8a5/6706095/32a5686b4514/jbm-6-2-e114-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8a5/6706095/1fb89d6ea890/jbm-6-2-e114-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8a5/6706095/ce5ae7b060ff/jbm-6-2-e114-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8a5/6706095/a915cec8790e/jbm-6-2-e114-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8a5/6706095/32a5686b4514/jbm-6-2-e114-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8a5/6706095/1fb89d6ea890/jbm-6-2-e114-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8a5/6706095/ce5ae7b060ff/jbm-6-2-e114-g004.jpg

相似文献

1
Detection of clinically relevant immune checkpoint markers by multicolor flow cytometry.通过多色流式细胞术检测临床相关免疫检查点标志物。
J Biol Methods. 2019 Jun 3;6(2):e114. doi: 10.14440/jbm.2019.283. eCollection 2019.
2
Development of an 8-color antibody panel for functional phenotyping of human CD8+ cytotoxic T cells from peripheral blood mononuclear cells.用于从外周血单个核细胞对人CD8 + 细胞毒性T细胞进行功能表型分析的八色抗体组合的开发。
Cytotechnology. 2018 Feb;70(1):1-11. doi: 10.1007/s10616-017-0106-3. Epub 2017 May 27.
3
Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients.TIM-3、LAG-3、PD-1和PD-L1作为免疫治疗检查点靶点在间皮瘤患者胸腹腔积液中大量表达。
Oncotarget. 2017 Sep 21;8(52):89722-89735. doi: 10.18632/oncotarget.21113. eCollection 2017 Oct 27.
4
Standardized 11-color flow cytometry panel for the functional phenotyping of human T regulatory cells.用于人类调节性T细胞功能表型分析的标准化11色流式细胞术检测板
J Biol Methods. 2020 Apr 13;7(2):e131. doi: 10.14440/jbm.2020.325. eCollection 2020.
5
Eight-Color Multiplex Immunohistochemistry for Simultaneous Detection of Multiple Immune Checkpoint Molecules within the Tumor Microenvironment.用于同时检测肿瘤微环境中多种免疫检查点分子的八色多重免疫组织化学
J Immunol. 2018 Jan 1;200(1):347-354. doi: 10.4049/jimmunol.1701262. Epub 2017 Nov 15.
6
Soluble immune checkpoint-related proteins as predictors of tumor recurrence, survival, and T cell phenotypes in clear cell renal cell carcinoma patients.可溶性免疫检查点相关蛋白作为预测透明细胞肾细胞癌患者肿瘤复发、生存和 T 细胞表型的标志物。
J Immunother Cancer. 2019 Nov 29;7(1):334. doi: 10.1186/s40425-019-0810-y.
7
Higher frequency of the CTLA-4 LAG-3 T-cell subset in patients with newly diagnosed acute myeloid leukemia.新诊断急性髓系白血病患者中CTLA-4 LAG-3 T细胞亚群的频率更高。
Asia Pac J Clin Oncol. 2020 Apr;16(2):e12-e18. doi: 10.1111/ajco.13236. Epub 2019 Oct 15.
8
Elevated Expression of Tim-3 and PD-1 Immune Checkpoint Receptors on T-CD4+ Lymphocytes of Patients with Asthma.哮喘患者T-CD4+淋巴细胞上Tim-3和PD-1免疫检查点受体的表达升高。
Iran J Allergy Asthma Immunol. 2018 Dec 2;17(6):517-525.
9
Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.基于痘病毒的主动免疫疗法与CTLA-4阻断协同作用,通过提高细胞毒性T细胞的数量和质量来提高小鼠肿瘤模型的生存率。
Cancer Immunol Immunother. 2016 May;65(5):537-49. doi: 10.1007/s00262-016-1816-7. Epub 2016 Mar 10.
10
Expression analysis of PD-1 and Tim-3 immune checkpoint receptors in patients with vitiligo; positive association with disease activity.PD-1 和 Tim-3 免疫检查点受体在白癜风患者中的表达分析;与疾病活动度呈正相关。
Exp Dermatol. 2019 Jun;28(6):674-681. doi: 10.1111/exd.13952.

引用本文的文献

1
In Vitro Generated Equine Hepatic-Like Progenitor Cells as a Novel Potent Cell Pool for Equine Metabolic Syndrome (EMS) Treatment.体外生成的马源类肝祖细胞作为治疗马代谢综合征(EMS)的新型有效细胞池。
Stem Cell Rev Rep. 2023 May;19(4):1124-1134. doi: 10.1007/s12015-023-10507-3. Epub 2023 Jan 20.
2
Immunophenotyping: Analytical approaches and role in preclinical development of nanomedicines.免疫表型分析:在纳米药物临床前开发中的分析方法和作用。
Adv Drug Deliv Rev. 2022 Jun;185:114281. doi: 10.1016/j.addr.2022.114281. Epub 2022 Apr 9.
3
Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse.

本文引用的文献

1
One-Tube Multicolor Flow Cytometry Assay (OTMA) for Comprehensive Immunophenotyping of Peripheral Blood.用于外周血全面免疫表型分析的单管多色流式细胞术检测(OTMA)
Methods Mol Biol. 2019;1904:189-212. doi: 10.1007/978-1-4939-8958-4_8.
2
Separation, banking, and quality control of peripheral blood mononuclear cells from whole blood of melanoma patients.从黑色素瘤患者全血中分离、保存及进行外周血单个核细胞的质量控制
Cell Tissue Bank. 2018 Dec;19(4):783-790. doi: 10.1007/s10561-018-9734-x. Epub 2018 Oct 30.
3
A curative treatment strategy using tumor debulking surgery combined with immune checkpoint inhibitors for advanced pediatric solid tumors: An in vivo study using a murine model of osteosarcoma.
输注供体记忆样自然杀伤细胞治疗移植后复发的扩增、持续和疗效。
J Clin Invest. 2022 Jun 1;132(11). doi: 10.1172/JCI154334.
4
On Demand Biosensors for Early Diagnosis of Cancer and Immune Checkpoints Blockade Therapy Monitoring from Liquid Biopsy.按需生物传感器在液体活检中用于癌症的早期诊断和免疫检查点阻断疗法监测。
Biosensors (Basel). 2021 Dec 7;11(12):500. doi: 10.3390/bios11120500.
5
Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial.联合 CTLA-4 和血管生成素-2 阻断治疗晚期黑色素瘤患者的 I 期临床试验。
J Immunother Cancer. 2021 Nov;9(11). doi: 10.1136/jitc-2021-003318.
6
Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival.帕博利珠单抗治疗难治性食管癌的 II 期研究:与反应和生存相关的因素。
J Immunother Cancer. 2021 Sep;9(9). doi: 10.1136/jitc-2021-002472.
7
Immune modulating activity of the CHK1 inhibitor prexasertib and anti-PD-L1 antibody LY3300054 in patients with high-grade serous ovarian cancer and other solid tumors.CHK1 抑制剂 prexasertib 和抗 PD-L1 抗体 LY3300054 对高级别浆液性卵巢癌和其他实体瘤患者的免疫调节活性。
Cancer Immunol Immunother. 2021 Oct;70(10):2991-3000. doi: 10.1007/s00262-021-02910-x. Epub 2021 Mar 20.
8
Full Spectrum Flow Cytometry as a Powerful Technology for Cancer Immunotherapy Research.全谱流式细胞术作为癌症免疫治疗研究的强大技术
Front Mol Biosci. 2021 Jan 29;7:612801. doi: 10.3389/fmolb.2020.612801. eCollection 2020.
9
Di-bromo-Based Small-Molecule Inhibitors of the PD-1/PD-L1 Immune Checkpoint.基于二溴的 PD-1/PD-L1 免疫检查点小分子抑制剂。
J Med Chem. 2020 Oct 8;63(19):11271-11285. doi: 10.1021/acs.jmedchem.0c01260. Epub 2020 Sep 23.
10
Standardized 11-color flow cytometry panel for the functional phenotyping of human T regulatory cells.用于人类调节性T细胞功能表型分析的标准化11色流式细胞术检测板
J Biol Methods. 2020 Apr 13;7(2):e131. doi: 10.14440/jbm.2020.325. eCollection 2020.
一种采用肿瘤减积手术联合免疫检查点抑制剂治疗晚期小儿实体瘤的治疗策略:一项使用骨肉瘤小鼠模型的体内研究。
J Pediatr Surg. 2018 Dec;53(12):2460-2464. doi: 10.1016/j.jpedsurg.2018.08.023. Epub 2018 Sep 2.
4
MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma.MHC 蛋白赋予未经治疗的转移性黑色素瘤对 CTLA-4 和 PD-1 阻断的不同敏感性。
Sci Transl Med. 2018 Jul 18;10(450). doi: 10.1126/scitranslmed.aar3342.
5
Inducible Co-Stimulator (ICOS) as a potential therapeutic target for anti-cancer therapy.诱导共刺激因子 (ICOS) 作为一种潜在的抗肿瘤治疗靶点。
Expert Opin Ther Targets. 2018 Apr;22(4):343-351. doi: 10.1080/14728222.2018.1444753. Epub 2018 Mar 1.
6
Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer.可溶性程序性死亡受体-1和程序性死亡配体-1:在癌症中的预测和预后意义
Oncotarget. 2017 May 31;8(57):97671-97682. doi: 10.18632/oncotarget.18311. eCollection 2017 Nov 14.
7
Development of an 8-color antibody panel for functional phenotyping of human CD8+ cytotoxic T cells from peripheral blood mononuclear cells.用于从外周血单个核细胞对人CD8 + 细胞毒性T细胞进行功能表型分析的八色抗体组合的开发。
Cytotechnology. 2018 Feb;70(1):1-11. doi: 10.1007/s10616-017-0106-3. Epub 2017 May 27.
8
Immune Checkpoint Inhibitors: An Innovation in Immunotherapy for the Treatment and Management of Patients with Cancer.免疫检查点抑制剂:癌症患者治疗与管理中免疫疗法的一项创新。
Asia Pac J Oncol Nurs. 2017 Apr-Jun;4(2):127-135. doi: 10.4103/apjon.apjon_4_17.
9
Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study.纳武单抗单药免疫治疗晚期子宫平滑肌肉瘤:一项2期研究的结果
Cancer. 2017 Sep 1;123(17):3285-3290. doi: 10.1002/cncr.30738. Epub 2017 Apr 25.
10
TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action.TIM-3作为癌症免疫治疗的靶点及作用机制
Int J Mol Sci. 2017 Mar 16;18(3):645. doi: 10.3390/ijms18030645.